Latest news from Oncolytics Biotech on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/expert-are-we-measuring-cancer-therapy-effectiveness-in-the-best-way/?sc=rsin /articles/expert-are-we-measuring-cancer-therapy-effectiveness-in-the-best-way/?sc=rsin Mon, 31 Oct 2016 09:00:19 EST Oncolytics Biotech /articles/expert-can-cancer-therapies-have-a-different-effectiveness-in-women/?sc=rsin /articles/expert-can-cancer-therapies-have-a-different-effectiveness-in-women/?sc=rsin Tue, 14 Jun 2016 08:50:13 EST Expert can speak on the importance of including women in clinical studies, a measure that could lead to improved, women-specific treatments. Brad Thompson, Ph.D., president and CEO of Oncolytics Biotech Inc., has overseen studies in colorectal cancer and non-small cell lung cancer in which female patients showed a significant response (relative to male patients) to a treatment that included the company's lead product, REOLYSIN(r), a proprietary formulation of the human reovirus. Oncolytics Biotech /articles/could-the-kras-gene-help-personalize-treatment-for-pancreatic-cancer/?sc=rsin /articles/could-the-kras-gene-help-personalize-treatment-for-pancreatic-cancer/?sc=rsin Thu, 09 Oct 2014 08:00:00 EST Researchers have known that treating a pancreatic cancer patient with human reovirus is only likely to be effective if the patient carries the mutant KRAS gene and not the wild-type KRAS gene. A recent Phase 2 clinical study by Oncolytics Biotech, Inc., involving their proprietary form of the human reovirus, REOLYSIN(r), has corroborated this link, pointing the way toward more personalized cancer care if mutant KRAS is used as a biomarker and prospective patients are screened in advance of treatment. Oncolytics Biotech /articles/for-colorectal-cancer-patients-new-hope-from-a-cancer-destroying-virus/?sc=rsin /articles/for-colorectal-cancer-patients-new-hope-from-a-cancer-destroying-virus/?sc=rsin Mon, 28 Jan 2013 10:45:00 EST Calgary-based Oncolytics Biotech Inc. has reported results for REOLYSIN from a phase 1 study in patients with colorectal cancer at the American Society of Clinical Oncology's 2013 Gastrointestinal Cancers Symposium (ASCO GI). Oncolytics Biotech /articles/could-a-virus-beat-the-mets-human-reovirus-may-help-treat-metastatic-cancer/?sc=rsin /articles/could-a-virus-beat-the-mets-human-reovirus-may-help-treat-metastatic-cancer/?sc=rsin Wed, 14 Nov 2012 09:00:00 EST Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets? Oncolytics Biotech /articles/hitch-hiking-viral-therapy-deals-a-double-blow-to-cancer/?sc=rsin /articles/hitch-hiking-viral-therapy-deals-a-double-blow-to-cancer/?sc=rsin Wed, 13 Jun 2012 14:00:00 EST Reovirus is a promising new way of treating cancer that attacks the disease on two fronts. Not only does the virus kill cancer cells directly, but it also triggers an immune response - like a vaccine - that helps eliminate residual cancer cells. Oncolytics Biotech /articles/new-study-spotlights-potential-of-virus-to-treat-certain-lung-cancer-patients/?sc=rsin /articles/new-study-spotlights-potential-of-virus-to-treat-certain-lung-cancer-patients/?sc=rsin Tue, 14 Jun 2011 06:00:00 EST Now a new study reports that reovirus has the potential to treat certain lung cancer patients, when the reovirus is combined with two other substances known as paclitaxel and carboplatin. Oncolytics Biotech /articles/the-future-of-cancer-clinical-trials-hold-promise-thanks-to-oncolytic-viruses/?sc=rsin /articles/the-future-of-cancer-clinical-trials-hold-promise-thanks-to-oncolytic-viruses/?sc=rsin Fri, 08 Apr 2011 13:00:00 EST There are a number of oncolytic viruses that have shown potential use in cancer treatment and demand for more effective agents is strong. Future research studies will give us an even clearer perspective on which, if any, of these viruses offer the most effective route toward a reliable and commercially viable complement to chemotherapy for oncologists and their patients. Oncolytics Biotech /articles/novel-study-using-reoviruses-against-ovarian-cancer-pushes-forward/?sc=rsin /articles/novel-study-using-reoviruses-against-ovarian-cancer-pushes-forward/?sc=rsin Mon, 13 Sep 2010 05:00:00 EST Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(r) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer. Oncolytics Biotech /articles/scientists-are-reolysin-the-power-of-live-biologics-to-fight-cancer-in-two-recent-studies32/?sc=rsin /articles/scientists-are-reolysin-the-power-of-live-biologics-to-fight-cancer-in-two-recent-studies32/?sc=rsin Mon, 14 Dec 2009 05:00:00 EST Live biologic therapies are offering new hope for patients affected by hard-to-treat cancers, according to two different studies that treated patients with sarcomas and head and neck cancers. Oncolytics Biotech /articles/cancer-killing-virus-may-be-the-answer-for-patients-with-kras-mutated-tumors/?sc=rsin /articles/cancer-killing-virus-may-be-the-answer-for-patients-with-kras-mutated-tumors/?sc=rsin Tue, 28 Jul 2009 06:00:00 EST For patients with mutations in KRAS, the good news is that an alternative therapy is currently being developed for them. An oncolytic virus being developed by Oncolytics Biotech Inc. can kill cancer cells with this particular mutation and with EGFR mutations as well, and is already well-advanced into clinical trials in the U.S. and the U.K. Oncolytics Biotech /articles/combination-of-chemo-and-common-virus-continues-to-show-remarkable-results-in-advanced-cancer-patients/?sc=rsin /articles/combination-of-chemo-and-common-virus-continues-to-show-remarkable-results-in-advanced-cancer-patients/?sc=rsin Fri, 03 Apr 2009 13:00:00 EST Chemotherapy is now often used in combination with other treatments that have different mechanisms for attacking and killing cancer cells. One such complimentary drug may be REOLYSIN, now being developed from the naturally occurring reovirus. Oncolytics Biotech /articles/common-virus-helps-quality-of-life-for-sarcoma-patients-says-cancer-expert/?sc=rsin /articles/common-virus-helps-quality-of-life-for-sarcoma-patients-says-cancer-expert/?sc=rsin Wed, 19 Nov 2008 11:25:00 EST New data presented by Dr. Monica Mita at the Cancer Therapy and Research Center at the University of Texas Health Science Center, shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives. Oncolytics Biotech /articles/new-approach-uses-a-common-virus-to-combat-deadly-lung-cancer/?sc=rsin /articles/new-approach-uses-a-common-virus-to-combat-deadly-lung-cancer/?sc=rsin Tue, 09 Sep 2008 07:00:00 EST Researchers at Ohio State University Medical Center are determining whether REOLYSIN, an experimental treatment derived from a common virus called the reovirus may help about 20% of the more than 180,000 non small cell lung cancer patients diagnosed every year in the U.S. that have mutations in the K-RAS gene. These patients generally respond poorly to standard chemotherapy treatments as well as newer, more targeted therapies called EGFR inhibitors. Oncolytics Biotech /articles/positive-interim-results-reported-of-uk-combination-reolysin-and-carboplatinpaclitaxel-trial/?sc=rsin /articles/positive-interim-results-reported-of-uk-combination-reolysin-and-carboplatinpaclitaxel-trial/?sc=rsin Thu, 10 Apr 2008 08:45:00 EST Dr. Kevin Harrington of The Institute of Cancer Research, London, presented results that several patients with head and neck patients evaluated to date have had excellent clinical and radiological responses to a combination of Reolysin and carboplatin/paclitaxel without appreciable toxicity. Oncolytics Biotech /articles/cancer-therapy-paradigm-shift-live-biologics-have-the-potential-to-treat-23-of-all-known-human-cancers/?sc=rsin /articles/cancer-therapy-paradigm-shift-live-biologics-have-the-potential-to-treat-23-of-all-known-human-cancers/?sc=rsin Fri, 04 Apr 2008 13:00:00 EST Expert Dr. Matt Coffey is available to discuss how oncolytic (cancer-killing) viruses represent an entirely new approach to cancer treatment. Several viruses, including the reovirus, or Respiratory Enteric Orphan virus, have shown a strong preference for killing cancer cells rather than healthy cells, but it is only recently that the science has matured enough to allow scientists and the medical community to pursue oncolytic viruses as safe and effective cancer therapies. Oncolytics Biotech /articles/reovirus-plus-radiation-act-synergistically-against-cancer/?sc=rsin /articles/reovirus-plus-radiation-act-synergistically-against-cancer/?sc=rsin Wed, 07 Nov 2007 18:00:00 EST Encouraging results from a recent U.K. Phase Ia/Ib clinical trial demonstrated that the addition of radiation enhanced the cancer-killing ability of Reolysin, an oncolytic reovirus formulation in patients with a variety of advanced or metastatic cancers. Oncolytics Biotech /articles/dealing-deadly-cancers-a-knockout-punch/?sc=rsin /articles/dealing-deadly-cancers-a-knockout-punch/?sc=rsin Thu, 10 May 2007 08:00:00 EST New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers. Recent studies indicate that reviruses works synergistically with standard anti-cancer drugs, providing significantly stronger responses than either agent alone. Oncolytics Biotech /articles/multi-tasking-reovirus-kills-cancer-cells-and-primes-immune-system-to-do-the-same/?sc=rsin /articles/multi-tasking-reovirus-kills-cancer-cells-and-primes-immune-system-to-do-the-same/?sc=rsin Thu, 08 Feb 2007 07:00:00 EST Accumulating data that suggests in addition to directly killing tumor cells, reoviruses may prime the immune system to mount a separate, powerful and long lasting defense against cancer. Oncolytics Biotech /articles/common-virus-significantly-enhances-cancer-fighting-ability-of-standard-chemotherapy-drugs/?sc=rsin /articles/common-virus-significantly-enhances-cancer-fighting-ability-of-standard-chemotherapy-drugs/?sc=rsin Mon, 20 Nov 2006 09:00:00 EST The NCI tested the Respiratory Enteric Orphan virus, or reovirus, a non-disease causing virus in combination with a number of widely used chemotherapy drugs. In general, the combination of reovirus with cisplatin, gemcitabine, mitomycin or vinblastine was found to be more effective against NSCLC cell lines sensitive to anti-cancer drugs than each treatment used on its own. Oncolytics Biotech